Targeting the Tumor Vasculature: From Vascular Normalization to Tumor Immunity
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 186
Special Issue Editor
Interests: tumor blood vessel morphogenesis; tumor immune surveillance; tumor endothelial cells; immune cells
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tumor expansion and metastasis crucially depend on the presence of functional vasculature. Angiogenic blood vessels establish uniform conduits that fulfill the tumor's metabolic demand for oxygen and nutrient supply. Beyond this foundational role, heterogeneous tumor vessels also serve as an immune barrier. Tumors evade immune surveillance through endothelial anergy, reinforcing the immune barrier via angiogenic factors. Despite extensive research, anti-angiogenic therapies have achieved only limited success, hindered by various factors including side effects, drug resistance, and tumor recurrence. Continuing advanced research strives to surmount the endothelial immune barrier in solid tumors while identifying novel factors that can normalize tumor blood vessels and amplify immune infiltration. Many elaborate approaches manipulate tumor vessels to normalize and enhance T-cell infiltration, thus providing a rationale for combining anti-angiogenic therapy and immunotherapy. This collection encompasses anti-angiogenic approaches integrated with immunotherapy, highlighting their potential to reshape tumor blood vessels and modulate immune responses.
Dr. Dae Joong Kim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor endothelial anergy
- immunotherapy
- angiogenic growth factors
- anti-angiogenic therapy
- vascular normalization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
